News for Verastem, Inc. (0LOV.L)

PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/

Nantahala Capital Management, LLC (Trades, Portfolio), a prominent investment firm, executed a significant stock transaction on December 31, 2024. The firm adde

On December 31, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) executed a significant transaction by acquiring an additional 427,030 shares of Verastem

Significant Transaction by Alyeska Investment Group On December 31, 2024, Alyeska Investment Group, L.P. (Trades, Portfolio) executed a notable transaction invo

On December 31, 2024, Barclays PLC executed a significant transaction by acquiring 3,894,093 shares of Verastem Inc (VSTM) at a price of $5.17 per share. This s

Introduction to the Transaction On December 31, 2024, Balyasny Asset Management L.P. (Trades, Portfolio) executed a noteworthy transaction by acquiring 3,945,92

On December 31, 2024, Vanguard Group Inc. made a significant move by acquiring an additional 382,816 shares of Verastem Inc. at a price of $5.17 per share. This

Verastem Inc. (VSTM), doing business as Verastem Oncology, Wednesday announced the appointment of Matthew Ros as chief operating officer. Previously, Ros had served as chief executive officer and board director at FORE Biotherapeutics, an oncology company.

Verastem, Inc.'s promising therapy for LGSOC could position them as a commercial-stage company by 2025, capturing a big market share. Click for my VSTM update.

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma. Click to read.

Following news that the U.S. Food and Drug Administration approved its New Drug Application for avutometinib in combination with defactinib to treat recurrent l

U.K.-based Aptorum Group Limited (APM) is up over 329 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Verastem director Brian Stuglik sells $4,160 in stock

Shares of General Dynamics Corporation GD fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Re...

Shares of Enphase Energy, Inc. ENPH rose sharply in today's pre-market trading after the company reported second-quarter financial results. Enphase Energy repo...

Loading... Loading... Shares of ASP Isotopes Inc. ASPI fell during Friday's session after the company announced pricing of a $30 million public offering of 12 ...

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1.

The cervical dysplasia market is expected to grow significantly owing to an increased screening rate and increasing initiatives to create public awareness....

Explore groundbreaking insights on GenFleet and Verastem's innovations in the China biotech landscape. Click here for more with China Bio Today's latest article.